Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)

NCT04855136 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04855136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04855136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Terminated
Start date
June 1, 2021
Completion date
April 25, 2025
Enrollment
21 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma